Premium
A comparative study of optimal medical care with and without azaserine in multiple myeloma
Author(s) -
Holland James F.,
Gehan Edmund A.,
Brindley Clyde O.,
Dederick Marguerida M.,
Owens Albert H.,
Shnider Bruce I.,
Taylor Robert,
Frei Emil,
Selawry Oleg S.,
Regelson William,
Hall Thomas C.
Publication year - 1961
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt19612122
Subject(s) - azaserine , multiple myeloma , medicine , placebo , medical care , oncology , pathology , glutamine , chemistry , biochemistry , emergency medicine , alternative medicine , amino acid
A comparative clinical study of optimal medical care plus azaserine versus optimal medical care plus a placebo was accomplished in 20 patients with multiple myeloma. Azaserine was originally studied in myeloma because of reported effects on a plasma cell neoplasm in mice. The controlled study was undertaken because suggestive activity in myeloma had previously been seen. The 9 azaserine‐treated patients sustained more toxicity than the 11 placebo‐treated patients. No important difference in tumor behavior was detectable between the azaserine and placebo‐treated groups as determined by physical examination or the several hematologic, biochemical, and roentgenologic measurements made.